AZNCF - AstraZeneca's Lynparza Label Expansion And Other News: The Good Bad And Ugly Of Biopharma
AstraZeneca and Merck Receive Lynparza Boost
AstraZeneca (AZN) and Merck & Co. (MRK) announced that their Lynparza has received the FDA nod for its fourth tumor type, prostate cancer. This PARP inhibitor is now authorized to be used for treating patients with previously treated metastatic, castration-resistant patients with mutations in their homologous recombination repair (HRR) genes. Earlier, the companies had stated that the drug also topped Zytiga and Xtandi at extending the lives of patients suffering from BRCA1, BRCA2 or ATM mutations.
The application was supported by the data collected from